Experimental and Clinical Research Center, Charité University Medicine - Max Delbrück Center (MDC) for Molecular Medicine Berlin, Germany ; Nephrology/Intensive Care Section, Charité University Medicine Berlin, Germany.
Front Physiol. 2014 Oct 6;5:381. doi: 10.3389/fphys.2014.00381. eCollection 2014.
Ischemia and reperfusion (IR) injury constitutes one of the major causes of cardiovascular morbidity and mortality. The discovery of new therapies to block/mediate the effects of IR is therefore an important goal in the biomedical sciences. Dysfunction associated with IR involves modification of calcium-activated potassium channels (KCa) through different mechanisms, which are still under study. Respectively, the KCa family, major contributors to plasma membrane calcium influx in cells and essential players in the regulation of the vascular tone are interesting candidates. This family is divided into two groups including the large conductance (BKCa) and the small/intermediate conductance (SKCa/IKCa) K(+) channels. In the heart and brain, these channels have been described to offer protection against IR injury. BKCa and SKCa channels deserve special attention since new data demonstrate that these channels are also expressed in mitochondria. More studies are however needed to fully determine their potential use as therapeutic targets.
缺血再灌注（IR）损伤是心血管发病率和死亡率的主要原因之一。因此，发现新的疗法来阻断/介导 IR 的影响是生物医学科学的一个重要目标。与 IR 相关的功能障碍涉及通过不同机制对钙激活钾通道（KCa）进行修饰，这些机制仍在研究中。分别来说，KCa 家族是细胞内质膜钙内流的主要贡献者，也是血管张力调节的重要参与者，是有趣的候选者。该家族分为两组，包括大电导（BKCa）和小/中等电导（SKCa/IKCa）K（+）通道。在心脏和大脑中，这些通道已被描述为提供对 IR 损伤的保护。BKCa 和 SKCa 通道值得特别关注，因为新数据表明这些通道也在线粒体中表达。然而，还需要更多的研究来充分确定它们作为治疗靶点的潜在用途。
